“A white space opportunity.” That’s how Enlaza Therapeutics Inc. co-founder and CEO Sergio Duron described to BioWorld the company’s efforts to develop the first covalent biologics, an endeavor that has gained the backing of an impressive group of investors in a recently closed $100 million series A round.

Related Keywords

Sergio Duron , Enlaza Therapeutics Inc , Enlaza Therapeutics , Covalent Biologics , Warlock , Bioworld Science , Refinancings , Newco News , Cancer , Antibody , Antibody Drug Conjugate , Protein , Series A ,